{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:47:27Z","timestamp":1782467247348,"version":"3.54.5"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Geriatr Med"],"DOI":"10.1007\/s41999-026-01460-8","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:45:36Z","timestamp":1775817936000},"page":"1111-1115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Age and neutrophil counts at the time of diagnosis of polymyalgia rheumatica: are they useful or confounding factors in the geriatrician\u2019s clinical practice?"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5348-3814","authenticated-orcid":false,"given":"Ciro","family":"Manzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"1","key":"1460_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/BOR.0000000000001059","volume":"37","author":"MM Sum","year":"2025","unstructured":"Sum MM, Pope JE (2025) Polymyalgia rheumatica and giant cell arteritis: diagnosis and management. Curr Opin Rheumatol 37(1):32\u201338. https:\/\/doi.org\/10.1097\/BOR.0000000000001059","journal-title":"Curr Opin Rheumatol"},{"issue":"10411","key":"1460_CR2","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(23)01310-7","volume":"402","author":"G Esp\u00edgol-Frigol\u00e9","year":"2023","unstructured":"Esp\u00edgol-Frigol\u00e9 G, Dejaco C, Mackie SL, Salvarani C, Matteson EL, Cid MC (2023) Polymyalgia rheumatica. Lancet 402(10411):1459\u20131472. https:\/\/doi.org\/10.1016\/S0140-6736(23)01310-7","journal-title":"Lancet"},{"issue":"1","key":"1460_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4081\/reumatismo.2018.1107","volume":"70","author":"F Muratore","year":"2018","unstructured":"Muratore F, Salvarani C, Macchioni P (2018) Contribution of the new 2012 EULAR\/ACR classification criteria for the diagnosis of polymyalgia rheumatica. Reumatismo 70(1):18\u201322. https:\/\/doi.org\/10.4081\/reumatismo.2018.1107","journal-title":"Reumatismo"},{"issue":"4","key":"1460_CR4","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","volume":"71","author":"B Dasgupta","year":"2012","unstructured":"Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M et al (2012) 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis 71(4):484\u2013492. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200329","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1460_CR5","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.semarthrit.2020.07.005","volume":"0","author":"A Sharma","year":"2020","unstructured":"Sharma A, Mohammad AJ, Turesson C (2020) Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: a systematic literature review. Semin Arthritis Rheum 0(5):1040\u20131048. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.07.005","journal-title":"Semin Arthritis Rheum"},{"key":"1460_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/medsci7090092","volume":"7","author":"C Manzo","year":"2019","unstructured":"Manzo C (2019) Incidence and prevalence of polymyalgia rheumatica (PMR): the importance of the epidemiological context. The Italian case. Med Sci 7:92. https:\/\/doi.org\/10.3390\/medsci7090092","journal-title":"Med Sci"},{"issue":"4","key":"1460_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/diseases6040084","volume":"6","author":"C Manzo","year":"2018","unstructured":"Manzo C (2018) Polymyalgia rheumatica (PMR) with normal values of both erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) concentration at the time of diagnosis in a centenarian man: a case report. Diseases 6(4):84. https:\/\/doi.org\/10.3390\/diseases6040084","journal-title":"Diseases"},{"key":"1460_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s41999-025-01399-2","author":"S \u00d6sken","year":"2026","unstructured":"\u00d6sken S, Tezcan ME (2026) Time to remission and steroid doses in older and younger patients with polymyalgia rheumatica. Eur Geriatr Med. https:\/\/doi.org\/10.1007\/s41999-025-01399-2","journal-title":"Eur Geriatr Med"},{"issue":"5","key":"1460_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.5114\/reum.2021.110600","volume":"59","author":"E Hysa","year":"2021","unstructured":"Hysa E, Ghorbannia A, Emamifar A, Milchert M, Manzo C (2021) Feasibility and usefulness of a fast-track clinic for patients suspected of polymyalgia rheumatica: notes for a work schedule through a narrative review of published literature. Reumatologia 59(5):323\u2013329. https:\/\/doi.org\/10.5114\/reum.2021.110600","journal-title":"Reumatologia"},{"key":"1460_CR10","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S0140-6736(17)31825-1","volume":"390","author":"MA Gonzalez-Gay","year":"2017","unstructured":"Gonzalez-Gay MA, Matteson EL, Castaneda S (2017) Polymyalgia rheumatica. Lancet 390:1700\u20131712. https:\/\/doi.org\/10.1016\/S0140-6736(17)31825-1","journal-title":"Lancet"},{"key":"1460_CR11","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/rheumatology\/key431","volume":"5","author":"C Manzo","year":"2019","unstructured":"Manzo C, Milchert M, Natale M, Brzosko M (2019) Polymyalgia rheumatica with normal values of both erythrocyte sedimentation rate and c-reactive protein concentration at the time of diagnosis. Rheumatology (Oxford 5:921\u2013923. https:\/\/doi.org\/10.1093\/rheumatology\/key431","journal-title":"Rheumatology (Oxford"},{"key":"1460_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.55563\/clinexprheumatol\/gdps1r","volume":"39","author":"DE Marsman","year":"2021","unstructured":"Marsman DE, den Broeder N, Boers N et al (2021) Polymyalgia rheumatica patients with and without elevated baseline acute phase reactants: distinct subgroups of polymyalgia rheumatica? Clin Exp Rheumatol 39:32\u201337. https:\/\/doi.org\/10.55563\/clinexprheumatol\/gdps1r","journal-title":"Clin Exp Rheumatol"},{"issue":"39","key":"1460_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035385","volume":"102","author":"M Kara","year":"2023","unstructured":"Kara M, Alp G, Ko\u00e7 AM (2023) Diagnostic difficulties in Polymyalgia Rheumatica cases with normal erythrocyte sedimentation rate and C-reactive protein values. Medicine (Baltimore) 102(39):e35385. https:\/\/doi.org\/10.1097\/MD.0000000000035385","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"1460_CR14","doi-asserted-by":"publisher","DOI":"10.12890\/2022_003192","volume":"9","author":"AE Mahgoub","year":"2022","unstructured":"Mahgoub AE, Tessema S, Nakhleh R (2022) Normal ESR, CRP and platelet count in Giant Cell Arteritis and Polymyalgia Rheumatica: a diagnostic conundrum. Eur J Case Rep Intern Med 9(2):003192. https:\/\/doi.org\/10.12890\/2022_003192","journal-title":"Eur J Case Rep Intern Med"},{"key":"1460_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-025-01732-x","author":"WA Schmidt","year":"2025","unstructured":"Schmidt WA (2025) Does polymyalgia rheumatica with normal CRP and ESR exist, and how should it be treated? Z Rheumatol. https:\/\/doi.org\/10.1007\/s00393-025-01732-x","journal-title":"Z Rheumatol"},{"issue":"11","key":"1460_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare13111226","volume":"13","author":"P Falsetti","year":"2025","unstructured":"Falsetti P, Manzo C, Isetta M, Placido F, Castagna A, Natale M et al (2025) Are there definite disease subsets in Polymyalgia Rheumatica? Suggestions from a narrative review. Healthcare Basel 13(11):1226. https:\/\/doi.org\/10.3390\/healthcare13111226","journal-title":"Healthcare Basel"},{"issue":"3","key":"1460_CR17","doi-asserted-by":"publisher","first-page":"184","DOI":"10.5114\/reum.2020.96549","volume":"58","author":"C Manzo","year":"2020","unstructured":"Manzo C, Milchert M, Natale M, Brzosko M (2020) Polymyalgia Rheumatica with normal inflammatory indices at the time of diagnosis: can we just move a step forward? Reumatologia 58(3):184\u2013186. https:\/\/doi.org\/10.5114\/reum.2020.96549","journal-title":"Reumatologia"},{"key":"1460_CR18","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.reuma.2010.09.001","volume":"7","author":"F Ceccato","year":"2011","unstructured":"Ceccato F, U\u00f1a C, Regidor M, Rillo O, Babini S, Paira S (2011) Conditions mimicking Polymyalgia Rheumatica. Reumatol Clin 7:156\u2013160. https:\/\/doi.org\/10.1016\/j.reuma.2010.09.001","journal-title":"Reumatol Clin"},{"key":"1460_CR19","first-page":"2179","volume":"27","author":"MA Gonzalez-Gay","year":"2000","unstructured":"Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, Olivieri I, Hunder GG (2000) The spectrum of conditions mimicking Polymyalgia Rheumatica in Northwestern Spain. J Rheumatol 27:2179\u20132184","journal-title":"J Rheumatol"},{"issue":"11","key":"1460_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/medicines7110068","volume":"7","author":"C Manzo","year":"2020","unstructured":"Manzo C, Isetta M, Natale M, Castagna A (2020) Identification and classification of Polymyalgia Rheumatica (PMR) and PMR-Like syndromes following Immune Checkpoint Inhibitors (ICIs) therapy: discussion points and grey areas emerging from a systematic review of published literature. Medicines Basel 7(11):68. https:\/\/doi.org\/10.3390\/medicines7110068","journal-title":"Medicines Basel"},{"issue":"Supplement_1","key":"1460_CR21","doi-asserted-by":"publisher","first-page":"i48","DOI":"10.1093\/rheumatology\/keae539","volume":"64","author":"L Iorio","year":"2025","unstructured":"Iorio L, Bond M, Padoan R, Dejaco C (2025) Advances in the treatment of polymyalgia rheumatica. Rheumatology (Oxford) 64(Supplement_1):i48\u2013i54. https:\/\/doi.org\/10.1093\/rheumatology\/keae539","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1460_CR22","doi-asserted-by":"publisher","first-page":"e233","DOI":"10.1016\/S2665-9913(24)00270-4","volume":"7","author":"A Saraux","year":"2025","unstructured":"Saraux A, Carvajal Alegria G, Dernis E, Roux C, Richez C, Tison A et al (2025) Baricitinib in early Polymyalgia Rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Rheumatol 7(4):e233\u2013e242. https:\/\/doi.org\/10.1016\/S2665-9913(24)00270-4","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"1460_CR23","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40744-025-00797-z","volume":"12","author":"P Harkins","year":"2025","unstructured":"Harkins P, Cowley S, Burke E, Harrington R, Molloy D, Kane D, Conway R (2025) Modern management of isolated Polymyalgia Rheumatica. Rheumatol Ther 12(6):1017\u20131041. https:\/\/doi.org\/10.1007\/s40744-025-00797-z","journal-title":"Rheumatol Ther"},{"issue":"2","key":"1460_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.70106","volume":"28","author":"M Sharma","year":"2025","unstructured":"Sharma M, Das SK, Mohindra R, Dutta D (2025) Efficacy and safety of Tocilizumab in Polymyalgia Rheumatica: a systematic review and meta-analysis. Int J Rheum Dis 28(2):e70106. https:\/\/doi.org\/10.1111\/1756-185X.70106","journal-title":"Int J Rheum Dis"},{"issue":"7","key":"1460_CR25","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/1744666X.2025.2521088","volume":"21","author":"S Casta\u00f1eda","year":"2025","unstructured":"Casta\u00f1eda S, Triguero-Mart\u00ednez A, Uriarte-Ecenarro M, Pardines-Ortiz M, Floranes P et al (2025) Unmet needs in the management of giant cell arteritis and polymyalgia rheumatica. Expert Rev Clin Immunol 21(7):835\u2013839. https:\/\/doi.org\/10.1080\/1744666X.2025.2521088","journal-title":"Expert Rev Clin Immunol"},{"issue":"10","key":"1460_CR26","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","volume":"74","author":"C Dejaco","year":"2015","unstructured":"Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S et al (2015) 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis 74(10):1799\u20131807. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207492","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"1460_CR27","doi-asserted-by":"publisher","first-page":"04592","DOI":"10.1016\/j.ard.2025.11.025","volume":"4967","author":"TE Bolhuis","year":"2025","unstructured":"Bolhuis TE, Kooijman NESEP, Marsman DE, Snijders GF, den Broeder AA, den Broeder N, van der Maas A (2025) Results of a 1-year randomised double-blind placebo-controlled trial with methotrexate 25 mg\/week in recently diagnosed polymyalgia rheumatica. Ann Rheum Dis. 4967(25):04592\u20133. https:\/\/doi.org\/10.1016\/j.ard.2025.11.025","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"1460_CR28","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.3390\/ijerph20031789","volume":"20","author":"R Ohta","year":"2023","unstructured":"Ohta R, Sano C (2023) Differentiating between seronegative elderly-onset rheumatoid arthritis and polymyalgia rheumatica: a qualitative synthesis of narrative reviews. Int J Environ Res Public Health 20(3):1789. https:\/\/doi.org\/10.3390\/ijerph20031789","journal-title":"Int J Environ Res Public Health"},{"key":"1460_CR29","first-page":"111","volume":"4","author":"C Manzo","year":"2019","unstructured":"Manzo C, Emamifar A (2019) Polymyalgia rheumatica and seronegative elderly-onset rheumatoid arthritis: two different diseases with many similarities. Eur Med J Rheumatol 4:111\u2013119","journal-title":"Eur Med J Rheumatol"},{"issue":"5","key":"1460_CR30","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1701\/2695.27559","volume":"108","author":"C Manzo","year":"2017","unstructured":"Manzo C, Camellino D (2017) Polymyalgia rheumatica: diagnostic and therapeutic issues of an apparently straightforward disease. Recenti Prog Med 108(5):221\u2013231. https:\/\/doi.org\/10.1701\/2695.27559. ([Article in Italian])","journal-title":"Recenti Prog Med"},{"issue":"3","key":"1460_CR31","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s10067-018-3988-3","volume":"37","author":"A Charpentier","year":"2018","unstructured":"Charpentier A, Verhoeven F, Sondag M, Guillot X, Prati C, Wendling D (2018) Therapeutic response to prednisone in relation to age in polymyalgia rheumatica: a comparison study. Clin Rheumatol 37(3):819\u2013823. https:\/\/doi.org\/10.1007\/s10067-018-3988-3","journal-title":"Clin Rheumatol"},{"issue":"1","key":"1460_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85857-4","volume":"11","author":"A Emamifar","year":"2021","unstructured":"Emamifar A, Ellingsen T, Hermann AP, Hess S, Gerke O, Ahangarani Farahani Z et al (2021) Prognostic impacts of glucocorticoid treatment in patients with polymyalgia rheumatica and giant cell arteritis. Sci Rep 11(1):6220. https:\/\/doi.org\/10.1038\/s41598-021-85857-4","journal-title":"Sci Rep"},{"issue":"12","key":"1460_CR33","doi-asserted-by":"publisher","first-page":"6036","DOI":"10.1093\/rheumatology\/keaf418","volume":"64","author":"Z Boyadzhieva","year":"2025","unstructured":"Boyadzhieva Z, Reisch M, Schneider M, Buttgereit F, Dejaco C (2025) Treatment and prognostic factors in PMR: a systematic literature review informing German, Austrian and Swiss guidelines. Rheumatology (Oxford) 64(12):6036\u20136047. https:\/\/doi.org\/10.1093\/rheumatology\/keaf418","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1460_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-005650","volume":"11","author":"Y Tanaka","year":"2025","unstructured":"Tanaka Y, Takahashi T, Fukasawa T, Inokuchi S, Uenaka H, Fujita A et al (2025) Trajectory analysis of glucocorticoid treatment highlights issues in the current tapering strategy for polymyalgia rheumatica. RMD Open 11(3):e005650. https:\/\/doi.org\/10.1136\/rmdopen-2025-005650","journal-title":"RMD Open"},{"issue":"2","key":"1460_CR35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3899\/jrheum.2024-0353","volume":"52","author":"MA Cimmino","year":"2025","unstructured":"Cimmino MA, Crowson CS, Dasgupta B, Schirmer M, Dejaco C, Salvarani C et al (2025) Symptom severity and glucocorticoid dosing in patients with polymyalgia rheumatica and obesity. J Rheumatol 52(2):151\u2013157. https:\/\/doi.org\/10.3899\/jrheum.2024-0353","journal-title":"J Rheumatol"},{"issue":"2","key":"1460_CR36","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/1756-185X.14054","volume":"24","author":"C Manzo","year":"2021","unstructured":"Manzo C (2021) C-reactive protein concentrations as predictors of glucocorticoid-free remission in patients with polymyalgia rheumatica. Int J Rheum Dis 24(2):284\u2013285. https:\/\/doi.org\/10.1111\/1756-185X.14054","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"1460_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105680","volume":"91","author":"Y Tanaka","year":"2024","unstructured":"Tanaka Y, Tanaka S, Fukasawa T, Inokuchi S, Uenaka H, Kimura T et al (2024) Glucocorticoid treatment and clinical outcomes in patients with polymyalgia rheumatica: a cohort study using routinely collected health data. Jt Bone Spine 91(3):105680. https:\/\/doi.org\/10.1016\/j.jbspin.2023.105680","journal-title":"Jt Bone Spine"},{"issue":"Suppl 135(9)","key":"1460_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.55563\/clinexprheumatol\/hb7van","volume":"41","author":"C Manzo","year":"2023","unstructured":"Manzo C, Nune A, Castagna A (2023) Why would immuno- and endocrino-senescence, age-related changes in the gut microbiota, and susceptibility to infection favour polymyalgia rheumatica over seronegative elderly-onset rheumatoid arthritis? Clin Exp Rheumatol 41(Suppl 135(9)):25\u201326. https:\/\/doi.org\/10.55563\/clinexprheumatol\/hb7van","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"1460_CR39","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5114\/reum\/200191","volume":"63","author":"C Manzo","year":"2025","unstructured":"Manzo C, Falsetti P, Castagna A, Isetta M, Conticini E (2025) When can calcium pyrophosphate deposition disease be considered a polymyalgia rheumatica mimicking disease? Reumatologia 63(3):182\u2013190. https:\/\/doi.org\/10.5114\/reum\/200191","journal-title":"Reumatologia"},{"issue":"2","key":"1460_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102995","volume":"21","author":"E Hysa","year":"2022","unstructured":"Hysa E, Gotelli E, Sammor\u00ec S, Cimmino MA, Paolino S, Pizzorni C et al (2022) Immune system activation in polymyalgia rheumatica: which balance between autoinflammation and autoimmunity? A systematic review. Autoimmun Rev 21(2):102995. https:\/\/doi.org\/10.1016\/j.autrev.2021.102995","journal-title":"Autoimmun Rev"},{"issue":"3","key":"1460_CR41","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/rheumatology\/ket292","volume":"53","author":"S Gay","year":"2014","unstructured":"Gay S, Wilson AG (2014) The emerging role of epigenetics in rheumatic diseases. Rheumatology (Oxford) 53(3):406\u2013414. https:\/\/doi.org\/10.1093\/rheumatology\/ket292","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1460_CR42","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1093\/rheumatology\/keae308","volume":"64","author":"SS Zhao","year":"2025","unstructured":"Zhao SS, Mackie SL, Larsson SC, Burgess S, Yuan S (2025) Modifiable risk factors and inflammation-related proteins in polymyalgia rheumatica: genome-wide meta-analysis and Mendelian randomization. Rheumatology (Oxford) 64(5):3012\u20133018. https:\/\/doi.org\/10.1093\/rheumatology\/keae308","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1460_CR43","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s10067-023-06708-3","volume":"43","author":"I Coskun Benlidayi","year":"2024","unstructured":"Coskun Benlidayi I (2024) Why is polymyalgia rheumatica a disease of older adults? Explanations through etiology and pathogenesis: a narrative review. Clin Rheumatol 43(3):851\u2013861. https:\/\/doi.org\/10.1007\/s10067-023-06708-3","journal-title":"Clin Rheumatol"},{"key":"1460_CR44","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2025.0830","author":"J Guo","year":"2025","unstructured":"Guo J, He Y, Yang F, Chen W (2025) Monocytes\/macrophages in giant cell arteritis-polymyalgia rheumatica spectrum disease. Aging Dis. https:\/\/doi.org\/10.14336\/AD.2025.0830","journal-title":"Aging Dis"},{"issue":"9","key":"1460_CR45","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41584-025-01279-w","volume":"21","author":"M Cutolo","year":"2025","unstructured":"Cutolo M, Soldano S, Smith V, Gotelli E, Hysa E (2025) Dynamic macrophage phenotypes in autoimmune and inflammatory rheumatic diseases. Nat Rev Rheumatol 21(9):546\u2013565. https:\/\/doi.org\/10.1038\/s41584-025-01279-w","journal-title":"Nat Rev Rheumatol"},{"key":"1460_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01981","volume":"10","author":"Y van Sleen","year":"2019","unstructured":"van Sleen Y, Graver JC, Abdulahad WH, van der Geest KSM, Boots AMH, Sandovici M, Brouwer E (2019) Leukocyte dynamics reveal a persistent myeloid dominance in giant cell arteritis and polymyalgia rheumatica. Front Immunol 10:1981. https:\/\/doi.org\/10.3389\/fimmu.2019.01981","journal-title":"Front Immunol"},{"issue":"5","key":"1460_CR47","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1136\/ard.27.5.397","volume":"27","author":"B Hamrin","year":"1968","unstructured":"Hamrin B, Jonsson N, Hellsten S (1968) Polymyalgia arteritica\". further clinical and histopathological studies with a report of six autopsy cases. Ann Rheum Dis 27(5):397\u2013405. https:\/\/doi.org\/10.1136\/ard.27.5.397","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1460_CR48","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1046\/j.1365-2249.1997.d01-946.x","volume":"107","author":"R Meliconi","year":"1997","unstructured":"Meliconi R, Pulsatelli L, Melchiorri C, Frizziero L, Salvarani C, Macchioni P, Uguccioni M, Focherini MC, Facchini A (1997) Synovial expression of cell adhesion molecules in polymyalgia rheumatica. Clin Exp Immunol 107(3):494\u2013500. https:\/\/doi.org\/10.1046\/j.1365-2249.1997.d01-946.x","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"1460_CR49","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1002\/art.1780390719","volume":"39","author":"R Meliconi","year":"1996","unstructured":"Meliconi R, Pulsatelli L, Uguccioni M, Salvarani C, Macchioni P, Melchiorri C, Focherini MC, Frizziero L, Facchini A (1996) Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment. Arthritis Rheum 39(7):1199\u20131207. https:\/\/doi.org\/10.1002\/art.1780390719","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1460_CR50","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/1756-185X.14000","volume":"24","author":"CE Owen","year":"2021","unstructured":"Owen CE, McMaster C, Liew DFL, Leung JL, Scott AM, Buchanan RRC (2021) Neutrophil to lymphocyte ratio predicts glucocorticoid resistance in polymyalgia rheumatica. Int J Rheum Dis 24(1):56\u201362. https:\/\/doi.org\/10.1111\/1756-185X.14000","journal-title":"Int J Rheum Dis"},{"issue":"9","key":"1460_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23000","volume":"33","author":"JY Jung","year":"2019","unstructured":"Jung JY, Lee E, Suh CH, Kim HA (2019) Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are associated with disease activity in polymyalgia rheumatica. J Clin Lab Anal 33(9):e23000. https:\/\/doi.org\/10.1002\/jcla.23000","journal-title":"J Clin Lab Anal"},{"issue":"10","key":"1460_CR52","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/ard.2003.011379","volume":"63","author":"BF Leeb","year":"2004","unstructured":"Leeb BF, Bird HA (2004) A disease activity score for polymyalgia rheumatica. Ann Rheum Dis 63(10):1279\u20131283. https:\/\/doi.org\/10.1136\/ard.2003.011379","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1460_CR53","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3899\/jrheum.110866","volume":"39","author":"C Cleuziou","year":"2012","unstructured":"Cleuziou C, Binard A, De Bandt M, Berthelot JM, Saraux A (2012) Contribution of the polymyalgia rheumatica activity score to glucocorticoid dosage adjustment in everyday practice. J Rheumatol 39(2):310\u2013313. https:\/\/doi.org\/10.3899\/jrheum.110866","journal-title":"J Rheumatol"},{"issue":"4","key":"1460_CR54","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/rheumatology\/kex477","volume":"57","author":"V Devauchelle-Pensec","year":"2018","unstructured":"Devauchelle-Pensec V, Saraux L, Berthelot JM, De Bandt M, Cornec D, Guellec D et al (2018) Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable. Rheumatology (Oxford) 57(4):666\u2013670. https:\/\/doi.org\/10.1093\/rheumatology\/kex477","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1460_CR55","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s00393-023-01358-x","volume":"82","author":"M Reisch","year":"2023","unstructured":"Reisch M, Dejaco C (2023) Methods for assessment of disease activity of polymyalgia rheumatica. Z Rheumatol 82(5):368\u2013379. https:\/\/doi.org\/10.1007\/s00393-023-01358-x. ([Article in German])","journal-title":"Z Rheumatol"}],"container-title":["European Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-026-01460-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41999-026-01460-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-026-01460-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:12:25Z","timestamp":1782465145000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41999-026-01460-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":55,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["1460"],"URL":"https:\/\/doi.org\/10.1007\/s41999-026-01460-8","relation":{},"ISSN":["1878-7657"],"issn-type":[{"value":"1878-7657","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"10 April 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}